GUFICBIO Gufic Biosciences Q2 FY26 results (Jul–Sep 2025) and concall
Gufic Biosciences reported a strong Q2 FY26 with modest revenue growth but significant margin expansion, primarily driven by the Indore plant's commercialization and increased international business. The company is focused on scaling its complex injectable portfolio, expanding regulatory reach, and optimizing capacity utilization at the new Indore facility. While domestic critical care faced pricing erosion, specialty segments like infertility and botulin toxin showed robust growth.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q2 FY26: revenue up 12.7%, net profit down 31.8% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|
| Revenue | 204 | 208 | 205 | 227 | 230 +13% |
| EBITDA | 39 | 34 | 27 | 32 | 36 −8% |
| Net profit | 22 | 19 | 8 | 12 | 15 −32% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
